

SCIENTIFIC PROGRAM



on AKI & CRRT
special edition

June 14-16, 2022

Vicenza Convention Centre



@vicenzacourse

ROOM A: AKI & SEPSIS

Joint session University of Melbourne/IRRIV

Chairs: *R. Bellomo – S. De Rosa*9.00 AKI in sepsis: mechanisms, phenotype and biotype *E. See*9.20 Sepsis and AKI: where are we? *J.L. Vincent*9.40 Role of micovesicles *V. Cantaluppi*

9.50 Audience interaction and meet the expert interview

ROOM B: AKI: NEW INSIGHTSChairs: *J. Prowle—M. Nadim*9.00 Snapshot on AKI worldwide *R. Mehta*9.20 AKI Risk : susceptibility, exposures and mitigators *M. Joannidis*9.40 Biomarkers derived AKI definition *J. Kellum*

9.50 Audience interaction and meet the expert interview

ROOM C: BASICS of CRRT

Joint session Purdue University/IRRIV

Chairs: *A. Brendolan—V. Narsimhan*9.00 Mechanisms of Transport in CRRT *W. Clark*9.20 CRRT Membrane structure and function *C. Ronco*9.40 New Technologies *V. Narsimhan*

9.50 Audience interaction and meet the expert interview

10.15—10.40 COFFEE BREAK

ROOM A: BIOMARKERSChairs: *M. Ostermann—T. Reis*10.40 Can we use biomarkers to guide AKI management? *A. Zarbock*11.00 Can we use biomarkers to guide CRRT ? *M. Meersch*11.20 Biomarkers of kidney function in AKI: where do we stand? *C. Nusslag*

11.40 Audience interaction and meet the expert interview

ROOM B: PREVENTION of AKI and RECOVERY PATTERNSChairs: *P. Romagnani—M. Okusa*10.40 Clinical patterns of recovery from AKI *L. Forni*11.00 Pathophysiological patterns of recovery from AKI *P. Romagnani*11.20 Alkaline Phosphatase in sepsis *P. Pickkers*

11.40 Audience interaction and meet the expert interview

ROOM C: BASICS OF ANTICOAGULATION

Joint session SITI/IRRIV

Chairs: *A. Tolwani—P. Navalesi*10.40 Principles of anticoagulation *G. Villa*11.00 Heparin-based anticoagulation *S. Samoni*11.20 Citrate-based anticoagulation *S. Romagnoli*

11.40 Audience interaction and meet the expert interview

12.00—12.30 LUNCH BREAK

PLENARY ROOM 12.30 45' Industry-Sponsored Session



PLENARY ROOM 13.15 30' Industry-Sponsored Session



PLENARY ROOM 13.45 15' Industry-Sponsored Session

**PLENARY ROOM**Chairs: *R. Mehta—A. Tolwani***AKI&SEPSIS (state of the art)**14.00 AKI in sepsis: mechanisms, phenotype and biotype *R. Bellomo*14.10 Sepsis and AKI: where are we? *S. De Rosa*

14.20 Discussion

AKI worldwide14.30 Snapshot on AKI worldwide *J. Prowle*14.40 AKI Risk : susceptibility, exposures and mitigators *M. Nadim*

14.50 Discussion

BASICS OF CRRT15.00 Mechanisms of Transport in CRRT *V. Narsimhan*15.10 CRRT Membrane structure and function *A. Brendolan*

15.20 Discussion

BIOMARKERS15.30 Can we use biomarkers to guide AKI management? *M. Ostermann*15.40 Can we use biomarkers to manage CRRT? *L. Forni*

15.50 Discussion

RECOVERY FROM AKI16.00 Clinical patterns of recovery from AKI *L. Forni*16.10 Pathophysiological patterns of recovery from AKI *M. Okusa*

16.20 Discussion

BASICS OF ANTICOAGULATION16.30 Principles and theory of anticoagulation *A. Tolwani*16.40 Heparin and citrate based anticoagulation in practice *G. Villa*

16.50 Discussion

PLENARY ROOM 17.00 45' Industry-Sponsored Session



PLENARY ROOM 17.45 30' Opening Ceremony



ROOM A: PERSISTENT AKI

Joint session UPMC/IRRIV

Chairs: *R. Murugan – S. Samoni*

- 9.00 Persistent AKI, a clinical and mechanistic fork in ICU patients *H. Gomez*
- 9.20 Persistent Kidney Dysfunction in Pediatric solid Organ Transplant *D. Fuhrman*
- 9.40 Persistent AKI: Precision medicine project *R. Murugan*
- 10.00 Audience interaction and meet the expert interview

ROOM B: ADSORPTION, A NEW FRONTIERChairs: *G. Ankawi – E. See*

- 9.00 Rationale for the use of adsorption in critical care medicine *R. Bellomo*
- 9.20 Hemoperfusion: mechanisms, indications and clinical application *C. Ronco*
- 9.40 Techniques of adsorption: from direct hemoperfusion to DPMAS *J. Prowle*
- 10.00 Audience interaction and meet the expert interview

ROOM C: DIGITAL HEALTH and AKI

Joint session Mayo Clinic/IRRIV

Chairs: *S. Bagshaw – D. Soranno*

- 9.00 Summary of ADQI consensus on digital health in AKI/CRRT *K. Kashani*
- 9.20 Using digital health of post-AKI management *A. Kattah*
- 9.40 Barriers in implementation and maintenance of digital health for AKI *D. Soranno*
- 10.00 Audience interaction and meet the expert interview

10.15—10.40 COFFEE BREAK

ROOM A: BLOOD PURIFICATION IN SEPSISChairs: *C. Ronco – M. Proglgio*

- 10.40 Why using EBP in sepsis? *J. Kellum*
- 11.00 Pathogen removal sepsis *L. Chawla*
- 11.20 Cytokine removal in sepsis *T. Rimmelé*
- 11.40 Audience interaction and meet the expert interview

ROOM B: AKI&CRRT in SEPSIS and Covid-19Chairs: *F. Husain-Syed – A. Nishio Lucar*

- 10.40 Extracorporeal support in leptospirosis and tropical diseases *N. Srisawat*
- 11.00 Report from ADQI consensus on prevention and management *M. Ostermann*
- 11.20 Clinical experience with PSP *G. Castellano*
- 11.40 Audience interaction and meet the expert interview

ROOM C: AKI&CRRT in PEDIATRICS

Joint session CCHMC/IRRIV

Chairs: *S. Goldstein - M. Zanella*

- 10.40 Worldwide and US experience with neonatal CRRT machine *C. Slagle*
- 11.00 AKI transition to CKD in pediatrics *D. Cooper*
- 11.20 Hemoperfusion in pediatric patients *G. Bottari*
- 11.40 Audience interaction and meet the expert interview

12.00—12.30 LUNCH BREAK

PLENARY ROOM 12.30 45' Industry-Sponsored Session



PLENARY ROOM 13.15 30' Industry-Sponsored Session



PLENARY ROOM 13.45 15' Industry-Sponsored Session

**PLENARY ROOM** Chairs: *H. Gomez – D. Fuhrman***PERSISTENT AKI**

- 14.00 Persistent AKI, a clinical and mechanistic fork in ICU patients
- 14.10 Persistent AKI: The precision medicine project
- 14.20 Discussion

S. Samoni
*R. Murugan***ADSORPTION, A NEW FRONTIER IN BLOOD PURIFICATION**

- 14.30 Rationale for the use of adsorption in critical care medicine
- 14.50 Hemoperfusion: mechanisms, indications and applications
- 15.00 Discussion

G. Ankawi
*T. Rimmelé***DIGITAL HEALTH AND AKI**

- 15.10 Using digital health of post-AKI management
- 15.20 Barriers in implementation and maintenance of digital health for AKI
- 15.30 Discussion

S. Bagshaw
*D. Soranno***EXTRACORPOREAL BLOOD PURIFICATION IN SEPSIS**

- 15.40 Membrane-based techniques in sepsis
- 15.50 Sorbent-based techniques in sepsis
- 16.00 Sequential extracorporeal therapy in sepsis
- 16.10 Discussion

G. Villa
C. Ronco
*S. De Rosa***AKI AND CRRT IN COVID 19: FROM FIRST WAVE TOOMICRON**

- 16.20 AKI in Covid-19: short and long term consequences
- 16.30 Report from ADQI consensus on AKI in Covid-19
- 16.40 Discussion

F. Husain-Syed
*T. Reis***AKI and CRRT in PEDIATRICS**

- 16.50 AKI in pediatrics and transition to CKD
- 17.00 CRRT in pediatrics: an update
- 17.10 Neonatal CRRT technology and outcomes
- 17.20 Discussion

S. Goldstein
Z. Ricci
C. Slagle

PLENARY ROOM 17.20 30' Industry-Sponsored Session



PLENARY ROOM 17.50 15' Industry-Sponsored Session



ROOM A: AKI BIOLOGY

Joint session UVA/IRRIV

Chairs: *M. Okusa – V. Cantaluppi*

- 9.00 Transplant AKI in times of COVID-19
A. Nishio Lucar
- 9.20 Cell Death and Clearance during AKI
S. Morioka
- 9.40 Pulsed Ultrasound to treat Inflammation and AKI
F. Husain-Syed
- 10.00 Audience interaction and meet the expert interview

ROOM B: BIOMARKERS IN CLINICAL PRACTICE

UCD Dublin-CHUM Montreal/IRRIV

Chairs: *A. Brendolan—P. Murray*

- 9.00 Biomarkers to differentiate functional versus intrinsic AKI
S. Duff
- 9.20 Implementation of AKI biomarkers in clinical practice
J-M. Côté
- 9.40 Biomarkers to predict AKI progression to CKD versus recovery
L. Redahan
- 10.00 Audience interaction and meet the expert interview

ROOM C: THERAPEUTIC APHERESISChairs: *M. Nadim—D. Fuhrman*

- 9.00 Emerging Trends in Extracorporeal Therapies (Apheresis) for AKI in Sepsis
R. Balogun
- 9.20 Immunoabsorption as a treatment options for neurological autoimmune disease
S.C. Boedecker-Lips
- 9.40 Immunoapheresis in ABO incompatible Transplant
P. Malvezzi
- 10.00 Audience interaction and meet the expert interview

10.15—10.40 COFFEE BREAK

ROOM A: EXTRACORPOREAL ORGAN SUPPORTChairs: *T. Rimmelé—M. Cannone*

- 10.40 Impact of Hemoperfusion on microcirculation in sepsis
C. Ince
- 11.00 Extracorporeal Lung Support
A. Combes
- 11.20 Extracorporeal Liver support
M. Nadim
- 11.40 Audience interaction and meet the expert interview

ROOM B: QUALITY MEASURES in AKI&CRRT

Joint session University of Alberta/IRRIV

Chairs: *S. Bagshaw – D. Soranno*

- 10.40 Digital Health Transformation and Implementation in AKI
N. Pannu
- 11.00 Quality Indicator and Best Practice Implementation in Acute RRT
O. Rewa
- 11.20 STARRT-AKI secondary studies and clinical Implications
S. Bagshaw
- 11.40 Audience interaction and meet the expert interview

ROOM C: FLUID OVERLOAD and MANAGEMENTChairs: *N. Aspromonte – A. Kattah*

- 10.40 Fluid overload: when diuretics fail
M. Ostermann
- 11.00 Current practice of extracorporeal fluid management
A. Kazory
- 11.20 Rationale for a new compact and portable ultrafiltration device
C. Ronco
- 11.40 Audience interaction and meet the expert interview

12.00—12.30 LUNCH BREAK

PLENARY ROOM 12.30 45' Industry-Sponsored Session



PLENARY ROOM 13.15 30' Industry-Sponsored Session



PLENARY ROOM 13.45 15' Industry-Sponsored Session

**PLENARY ROOM** Chairs: *M. Ostermann – A. Zarbock***AKI BIOLOGY**

- 14.00 Transplant AKI in times of COVID-19
- 14.10 Cell Death and Clearance during AKI
- 14.20 Pulsed Ultrasound to treat Inflammation and AKI
- 14.30 Discussion

A. Nishio Lucar
S. Morioka
*F. Husain-Syed***BIOMARKERS IN CLINICAL PRACTICE**

- 14.40 Biomarkers of Drug-induced Acute Kidney Injury
- 14.50 Biomarkers to differentiate functional versus intrinsic AKI
- 15.00 Implementation of AKI biomarkers in clinical practice
- 15.10 Discussion

P. Murray
S. Duff
*J-M. Côté***APHERESIS AND EXTRACORPOREAL ORGAN SUPPORT**

- 15.20 Emerging Trends in Extracorporeal Therapies (Apheresis) for AKI in Sepsis
- 15.30 Immunoabsorption as a treatment options for neurological autoimmune disease
- 15.40 Organ ex vivo perfusion for transplantation & marginal organ recovery
- 15.50 Discussion

R. Balogun
S.C. Boedecker-Lips
*A. Bertacco***ECOS**

- 16.00 Circulatory effects of hemoperfusion
- 16.10 Extracorporeal Lung support
- 16.20 Extracorporeal Liver support
- 16.30 Discussion

C. Ince
A. Combes
*M. Nadim***QUALITY MEASURES in AKI & CRRT**

- 16.40 Digital Health Transformation and Implementation in AKI
- 16.50 Quality Indicator and Best Practice Implementation in Acute RRT
- 17.00 STARRT-AKI secondary studies and clinical implications
- 17.10 Discussion

N. Pannu
O. Rewa
*S. Bagshaw***FLUID OVERLOAD MANAGEMENT**

- 17.20 Fluid overload: when diuretics fail
- 17.30 Current practice of extracorporeal fluid management
- 17.40 Discussion

N. Aspromonte
*A. Kattah***CONCLUSION**